Tirzepatide and Ipamorelin
Does adding ipamorelin to tirzepatide stop you losing muscle, or is that just a story vendors tell?
Reviewed by the amino101 editorial team. .
Also searched as GLP-1 muscle preservation stack, tirzepatide ipamorelin combo, Zepbound ipamorelin stack, Mounjaro and ipamorelin.
Tirzepatide is a once-weekly peptide that activates both the GIP and GLP-1 receptors, producing average weight loss of about 20 percent at the top dose in trials. It is sold as Mounjaro for diabetes and Zepbound for weight management and sleep apnea.
Ipamorelin is a pentapeptide that triggers growth hormone release through the ghrelin receptor without the cortisol, prolactin, or hunger spikes seen with older GHRPs. It is the most popular GHRP in the community, usually stacked with a GHRH analog.
People add ipamorelin to tirzepatide because of a real problem and a plausible fix. The problem: rapid weight loss on GLP-1 drugs takes lean mass with it. Reviews estimate that 30 to 40 percent of the weight lost may be fat-free mass, and the STEP 1 DEXA substudy of semaglutide found roughly 39 percent of weight lost was lean mass. The proposed fix: a growth hormone secretagogue raises growth hormone and IGF-1, which are anabolic, so the stack should tilt the loss toward fat. The honest state of the evidence: no human trial shows that ipamorelin, or any secretagogue, prevents lean mass loss during GLP-1 treatment. Tirzepatide's 20 percent weight loss at 15 mg in SURMOUNT-1 is among the best documented results in this field. Ipamorelin's effect on body composition, on or off a GLP-1, has never been measured in an outcome trial.
This is the trending stack of 2026 and the one with the biggest gap between the marketing and the data. It is also not a dangerous combination; the two have no known pharmacological conflict and the compound pages list them as compatible. The question is whether the ipamorelin earns its cost next to the two things that are actually proven to protect muscle on a GLP-1: resistance training and protein intake. This page covers dosage, what the ipamorelin can and cannot do, and the evidence-backed counters. Tirzepatide is an approved drug; ipamorelin is not. The GLP-1 muscle loss article goes deeper on the numbers. Educational only.
Why people combine Tirzepatide and Ipamorelin
Growth hormone and IGF-1 promote protein synthesis and lipolysis, and a bedtime ipamorelin pulse raises both in a way that human pilot studies have measured. During a large calorie deficit, those signals are low. That is the mechanism argument and it is not unreasonable. It is also where the evidence ends.
Tirzepatide is a once weekly incretin agonist with a 5 day half-life. Ipamorelin is a short acting GHRP with a 2 hour half-life, dosed fasted at bedtime. They do not share a receptor, a metabolic pathway or a side effect profile. The only tension is that ipamorelin acts on the ghrelin receptor and can nudge hunger up, slightly working against the appetite suppression.
Tirzepatide users eat less and often finish eating early. The ipamorelin needs an empty stomach, at least 2 hours after the last meal, and the natural nighttime growth hormone pulse. The schedules fit together without effort, which is part of why the stack caught on.
No human trial shows ipamorelin, sermorelin, CJC-1295 or tesamorelin prevents lean mass loss during GLP-1 treatment. The two things that do have evidence are resistance training two to four times a week and higher protein intake, with most guidance landing somewhere around 1.2 to 1.6 grams per kilogram of body weight a day, and both work without a second injection. Ipamorelin also raises glucose in the hours after a dose and can increase appetite, neither of which is what a tirzepatide user wants.
Tirzepatide and Ipamorelin dosage and protocol
What appears in research and community protocols for each compound in the stack. Not a prescription.
| Peptide | Dosage | Frequency | Timing and route |
|---|---|---|---|
| Tirzepatide | 2.5 mg start, increasing by 2.5 mg every 4 weeks to 5, 10 or 15 mg | once weekly | subcutaneous, abdomen, thigh or upper arm, same day each week, with or without food |
| Ipamorelin | 100 to 300 mcg | once daily before bed; 100 mcg if paired with a GHRH analog | subcutaneous, belly or thigh, on an empty stomach at least 2 hours after eating, no food for 20 to 30 minutes after |
Tirzepatide is not cycled; it is a stepwise titration held at whatever dose controls appetite, with a taper rather than a cold stop. Ipamorelin is conventionally run 8 to 16 weeks then paused for a few weeks, so people cycle it on and off underneath a continuous tirzepatide schedule, often timing a run to the months of fastest loss. IGF-1 and fasting glucose at baseline and every few months are the practical checks.
- •Ipamorelin is often paired with 100 mcg of Mod GRF 1-29 for a larger pulse; that turns this into a three compound stack, and the CJC-1295 and ipamorelin page covers the pair.
- •Fasting glucose needs watching. Growth hormone pulses raise glucose in the hours after a dose, and tirzepatide users with prediabetes are often on it for exactly that reason.
- •If appetite creeps up after starting ipamorelin, that is the ghrelin receptor. Dropping to 100 mcg or moving the dose later usually settles it.
- •Resistance training and protein are where the muscle preservation evidence sits, not in the ipamorelin vial.
Work out syringe units for any of these in the dosage calculator.
Can you mix Tirzepatide and Ipamorelin in one syringe?
These are never mixed. Tirzepatide is injected once a week and ipamorelin every night, the two are reconstituted at very different concentrations, and branded Zepbound or Mounjaro pens cannot be opened anyway. Each goes in its own syringe at its own time, with the tirzepatide on a fixed weekday and the ipamorelin at bedtime, and nobody sells a tirzepatide and ipamorelin blend. The tirzepatide dosage chart covers the weekly steps and the insulin syringe units chart covers drawing both from vials of different strengths.
What to expect, week by week
- Week 1 to 4
Appetite drops at 2.5 mg of tirzepatide, with mild nausea and early fullness. Ipamorelin gives flushing or lightheadedness after the first few doses and deeper sleep within the first week or two.
- Week 4 to 12
Loss of 1 to 2 pounds a week as the tirzepatide dose climbs. IGF-1 measurably higher by about week 4. This is the window where lean mass loss is fastest and where training and protein matter most.
- Month 3 to 6
Steady loss at the maintenance dose, GI effects settle, most people are 10 percent or more down. A DEXA scan here is the only honest way to know how much was muscle.
- Month 6 to 18
Loss slows toward a plateau near 15 to 20 percent depending on dose. Ipamorelin runs come and go; no trial has measured what they changed.
Side effects and cautions
- ▲Nausea and reduced appetite, worst after each tirzepatide dose increase
- ▲Diarrhea or constipation
- ▲Burping, reflux and indigestion
- ▲Headache, flushing or lightheadedness shortly after the ipamorelin dose
- ▲Water retention and puffy hands at higher ipamorelin doses, which can mask fat loss on the scale
- ▲Mild appetite increase from ipamorelin in some people, working against the tirzepatide
- ▲Fatigue, hair shedding and injection site reactions from either
- ■Prediabetes, diabetes or anyone on insulin or a sulfonylurea. Tirzepatide lowers glucose and raises hypoglycemia risk with those drugs, while ipamorelin pushes glucose up after each dose. That needs a clinician who knows about both.
- ■A personal or family history of medullary thyroid cancer or MEN2, the tirzepatide boxed warning, and any active or hormone sensitive cancer, which rules out raising IGF-1.
- ■Severe or persistent abdominal pain. Pancreatitis is rare, but the UK MHRA issued a safety alert in January 2026 describing it as an infrequent but potentially fatal GLP-1 side effect.
- ■Anyone adding ipamorelin instead of resistance training and protein. That is the one scenario where the stack is worse than tirzepatide alone, because it substitutes an unproven injection for the proven fix.
Tirzepatide and ipamorelin is not a bad combination; it is an unproven one marketed as if it were proven. The tirzepatide does the work, with about 20 percent weight loss at 15 mg in trials, and the ipamorelin adds a nightly growth hormone pulse that may help sleep and recovery and has never been shown to protect muscle during a GLP-1 cut. For someone already lifting three times a week, eating enough protein and getting a DEXA scan, ipamorelin is a defensible extra with mild side effects and a bloodwork requirement. For someone not doing those things, it is a distraction that costs money, nudges appetite and glucose in the wrong direction, and replaces the fix that works with one that might. The sensible order is tirzepatide alone first, then the training and the protein, then ipamorelin as a sleep and recovery aid if the budget and the bloodwork allow, never as a muscle guarantee. Diabetes, a cancer history or a pancreatitis history rules it out. Educational only; see semaglutide vs tirzepatide for the GLP-1 choice itself.
Tirzepatide and Ipamorelin: frequently asked
Does ipamorelin prevent muscle loss on tirzepatide?
No trial has shown that. Growth hormone and IGF-1 are anabolic, so the idea is plausible, but no human study of ipamorelin, sermorelin, CJC-1295 or tesamorelin during GLP-1 treatment has measured lean mass. The evidence-backed counters are resistance training and protein, covered in the GLP-1 muscle loss article.
How much muscle do you lose on tirzepatide?
Reviews estimate 30 to 40 percent of weight lost on GLP-1 drugs may be fat-free mass, and the STEP 1 DEXA substudy of semaglutide found about 39 percent. That is not unique to the drugs; any large, fast loss includes lean tissue. Protein and lifting shift the ratio toward fat.
What is the tirzepatide and ipamorelin dosage?
Tirzepatide follows its label: 2.5 mg weekly for 4 weeks, then up by 2.5 mg no sooner than every 4 weeks to a maintenance of 5, 10 or 15 mg. Ipamorelin is reported at 100 to 300 mcg before bed on an empty stomach, or 100 mcg with a GHRH analog. The tirzepatide dosage chart has the steps.
Will ipamorelin make me hungry on tirzepatide?
Slightly, for some people. It acts on the ghrelin receptor, though nothing like GHRP-6. If appetite climbs after starting it, 100 mcg rather than 300 mcg and a later bedtime dose usually fix it. If it keeps undermining the tirzepatide, most people drop it.
Can you take ipamorelin and tirzepatide at the same time?
Not in the same injection, and not usually at the same hour. Tirzepatide is once weekly, any time, with or without food. Ipamorelin is nightly on an empty stomach. They coexist on a calendar, not in a syringe.
Is tesamorelin better than ipamorelin for muscle on a GLP-1?
Tesamorelin has trial data for visceral fat, not for lean mass preservation, and the same point applies: no secretagogue has been shown to prevent muscle loss on a GLP-1. The tesamorelin and ipamorelin page covers that pair. For muscle, the answer is still the gym.
Related reading
Pulsatile growth hormone release
Visceral fat loss with growth hormone support
Weight loss beyond semaglutide alone
The two approved GLP-1 drugs went head to head. What does the result mean for you?
The triple agonist beats the dual agonist on paper. Is it worth waiting for, or buying early?
The two halves of the most popular GH stack. What does each one do, and which CJC-1295 are you actually buying?
One is a GHRP, one is a GHRH analog. Why are they compared, and why are they usually combined?
An approved GHRH analog with fat loss trials versus the community's favorite GHRP.
GLP-1
Sources
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022
- Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021
- Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998